Abbott Labs reported 6.9% sales growth in Q3 2025, led by medical devices and nutrition, while reaffirming full-year guidance ...

Abbott Laboratories ABT is slated to report third-quarter 2025 results on Oct. 15, before the opening bell. The company delivered adjusted earnings per share (EPS) of $1.26 in the last quarter, which ...

Medical devices continue to be a strong growth driver for Abbott, as the company battles its ongoing sales slump in ...

Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Abbott trimmed its earnings forecast as the Trump administration launched an investigation into medical device imports that ...

Abbott missed analysts' third-quarter revenue estimates on Wednesday, as weakness in its diagnostics and nutrition businesses outweighed robust demand for its medical devices.

Abbott reported higher quarterly revenue on Wednesday, driven by strong demand for its medical devices including continuous ...

Abbott (NYSE: ABT) shares dipped before hours today on third-quarter results that fell short of the consensus Wall Street ...

Abbott Laboratories (NYSE:ABT) develops, manufactures, and sells healthcare products, including pharmaceuticals, diagnostics, ...

Abbott Laboratories will divest its eye care division to Johnson & Johnson for about $4.33 billion in cash, reported Reuters. Here are five things to know about the deal. Abbott, which recently ...

Abbott Park, Ill.-based Abbott Laboratories reported better-than-expected sales and profit for its second quarter, largely due to its sales in the medical device market, according to Reuters. Sales ...

A federal judge handed Abbott Laboratories another win this week in its yearslong battle over the safety of its formulas for babies born prematurely — a decision that could have implications for ...